

MB THERAPEUTICS RAISES €2 MILLION TO INDUSTRIALIZE AND LAUNCH A SOLUTION FOR THE MANUFACTURING OF PERSONALIZED MEDICINES IN PHARMACIES



- This €2 million seed round aims to finance the world's first pharmaceutical facility dedicated to producing solutions compatible with 3D printing technology in pharmacies. The startup seeks to enable compounding pharmacies to manufacture next-generation personalized medicines for their patients.
- Every year, approximately 40 million patients in Europe benefit from medicines compounded in community and hospital pharmacies based on specific prescriptions. This global market is rapidly expanding, estimated at \$12 billion with an annual growth rate of 7%.

Montpellier (France), February 24, 2025 - MB Therapeutics, a Montpellier-based startup specializing in 3D printing of personalized medicines, has announced the closing of a €2 million fundraising round. This funding round is led by Beprep, Calyseed, Angels Santé, the "Banque Publique d'Investissement" (BPI), and Business Angels, particularly expert pharmacists such as Sébastien Gallice, co-owner of "Pharmacie des Rosiers" and President of the French Society of Compounding Pharmacists (PREF).

A tailored response to patients' needs

In the context of personalized medicine, where patient needs are becoming increasingly specific, 3D printing of medicines paves the way for a new era of therapeutic care. This technology enables precise dosage adjustments for adults suffering from hypertension or the creation of child-friendly formulations. Unlike the standardized "one-size-fits-all" approach, it offers tailor-made solutions while improving the quality and reproducibility of the drug manufacturing process.

Currently, over 1,000 community and hospital pharmacies across Europe specialize in drug compounding. These preparations are mainly done manually, which presents several challenges: enhancing quality standards, boosting production capacity to address drug shortages, and meeting the rising demand for personalized medicine. MB Therapeutics provides pharmacies with cutting-edge 3D printing technology and pre-filled cartridges with standardized pharmaceutical formulations, enabling on-site manufacturing of oral dosage forms, including orodispersible tablets. By integrating this innovation into their compounding labs, pharmacies significantly enhance staff safety, productivity, and preparation quality while ensuring traceability and compliance with regulatory requirements.

MB Therapeutics positions itself as the sole market player offering a turnkey industrial-quality solution for pharmaceutical compounding.

Combating drug shortages and pharmaceutical waste

This fundraising comes at a time when managing the demand for specialized medicines and reducing pharmaceutical waste are becoming critical issues. According to Report No. 2214 from the French National Agency for Medicines and Health Products Safety (ANSM), the number of reported drug shortages and supply risks has increased tenfold in the past ten years.

MB Therapeutics is revolutionizing drug production and addressing contemporary challenges by reducing logistical dependencies and minimizing waste: "Local production in community or hospital pharmacies of tailor-made medicines ensures rapid availability and precise dosages, essential for urgent and personalized care," explained Dr. Stéphane Roulon, CEO and Co-founder of MB Therapeutics.

A vision for the future of medicine

MB Therapeutics aligns with the global vision of the future of medicine. The shift towards individualized treatments is gaining traction in the pharmaceutical industry, with ongoing partnerships in development. The startup is pioneering a technology that enables all healthcare stakeholders to produce next-generation medicines tailored to the specific needs of each patient.

MB Therapeutics aims to lead the way in personalized treatments, playing a key role from the early stages of developing new oral dosage forms. The company envisions a future where personalized medicines are accessible to all, everywhere.

This funding round will enable the launch of three high-demand medicines in preparation for a Series A funding round in 2026.



Ian Soulairol & Stéphane Roulon, co-founders of MB Therapeutics

About MB Therapeutics:

Based in Montpellier, MB Therapeutics is a pioneering startup in 3D printing of personalized medicines. With over 10 years of expertise, its multidisciplinary team collaborates with key partners such as the University Hospital of Nîmes. By developing unique formulations adapted for pediatric use, the company stands at the forefront of personalized medicine, designing safe and effective tailor-made treatments.

About Calyseed:

Calyseed is a seed fund specializing in the healthcare sector. Its primary goal is to significantly increase the success rate of "Deeptech" startups through financial support and operational guidance during the critical early phase, from inception to initial funding rounds.

About Sébastien Gallice:

Sébastien Gallice, a graduate of ESSEC and a pharmacist, has over 20 years of experience in the pharmaceutical industry, primarily in infectious diseases. He later specialized in compounding by acquiring the compounding lab of Pharmacie des Rosiers in Marseille, gaining over 10 years of expertise in personalized medicine. As President of PREF, he is a key interlocutor with French regulatory authorities.

About Beprep:

Beprep is a leader in the field of magistral preparation. Formed by four independent regional compounding labs, it now represents the largest network of independent subcontracting pharmacies in France, employing over 150 staff across four specialized sites.

About Angels Santé:

As Europe's leading healthcare Business Angels network, Angels Santé plays a crucial role in healthcare startup funding. Active in France and across Europe, it is a key player in early-stage health investments and is a board member of the European Business Angels Network (EBAN) and a member of Business Angels Europe (BAE).

About Bpifrance ("Banque Publique d'Investissement"):

Bpifrance finances businesses at every stage of their development through loans, guarantees, and equity investments. It supports innovation projects and international expansion while offering export assistance via a wide range of financial products. Additionally, Bpifrance provides consulting, networking opportunities, and accelerator programs for startups, SMEs, and mid-sized companies.

Press Contacts - MB Therapeutics:

Stéphane Roulon

Co-Founder, CEO

stephane.roulon@mb-therapeutics.com

+33 6 21 50 44 82

Anaïs Ropero

Head of communications

anaïs.ropéro@mb-therapeutics.com

+33 6 40 52 10 60

Access MB Therapeutics media resources:

[Seed-MB-Press photo](#)

[Seed-MB-Press video](#)

Sources:

<http://pediatrics.aappublications.org/content/pediatrics/135/1/49.full.pdf>

<https://publications.aap.org/pediatrics/article-abstract/134/2/e354/32966/Unit-of-Measurement-Used-and-Parent-Medication?redirectedFrom=fulltext>

[https://www.lequotidiendumedecin.fr/sante-societe/politique-de-sante/17-600-tonnes-de-medicaments-jetes-en-france#:~:text=En%20France%20les%20m%C3%A9nages%20auraient,li%C3%A9s%20au%20type%20de%20m%C3%A9dicament.](https://www.lequotidiendumedecin.fr/sante-societe/politique-de-sante/17-600-tonnes-de-medicaments-jetes-en-
france#:~:text=En%20France%20les%20m%C3%A9nages%20auraient,li%C3%A9s%20au%20type%20de%20m%C3%A9dicament.)